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Abstract. Artemisinin derivatives are first-line antimalarial drugs in Thailand. No firm evidence of clinically relevant
artemisinin resistance exists. When used as monotherapy, artesunate has been associated with a high treatment failure
(recrudescence) rate, which could be due to low-level artemisinin resistance. To understand the causes of recrudescence,
we retrospectively studied a cohort of 104 malaria patients treated with artesunate monotherapy, 32 of whom recru-
desced. There was no difference in in vitro artesunate sensitivities between 6 nonrecrudescent isolates and 16 paired
admission and recrudescent isolates. Paired admission and recrudescent isolates from 10 patients were genotyped; only
3 had pfmdr1 mutations. Patients with admission parasitemias >10,000 per l had a 9-fold higher likelihood of recru-
descence (adjusted odds ratio) compared with patients with lower parasitemias. This study suggests (1) recrudescence
after treatment with artesunate is not the result of inherent parasite resistance, and (2) admission parasitemia may be
useful in choosing therapeutic options.
INTRODUCTION
Falciparum malaria has developed resistance to most cur-
rent antimalarials.1 Multidrug-resistant falciparum malaria is
particularly common in Southeast Asia, where it has greatly
limited therapeutic options. Artemisinin and its derivatives
are the only remaining drugs that are effective against severe
malaria and against multidrug-resistant malaria.2 Accord-
ingly, artesunate, a semisynthetic derivative of artemisinin, in
combination with mefloquine, is now the first-line treatment
of malaria in certain regions of Thailand, where it has been
used widely since 1992.3
Although different isolates of Plasmodium falciparum vary
in sensitivity to artemisinin in vitro, there is currently no hard
evidence for the existence of artemisinin resistance in vivo.
There have been reports of patients who failed therapy with
artemisinins, but when patient isolates were tested in vitro,
there was no evidence for decreased parasite susceptibility to
drug.4–6 Artemisinin-resistant murine malarias have been
generated and characterized.7 There are 3 possible reasons
why clinically important artemisinin resistance has not yet
appeared. First, artemisinin derivatives now are usually used
in combination with other drugs, and combination chemo-
therapy slows down the development of resistance.1 Second,
artemisinins have gametocytocidal activity, and this may in-
hibit the transmission of drug-resistant strains from person to
person.8 Third, artemisinin derivatives have short half-lives,
and drugs with short half-lives tend to be less prone to devel-
oping resistance.9
When used as monotherapy, artemisinin derivatives are as-
sociated with high rates of recrudescence.10 These recrudes-
cences could be due to either parasite factors (resistance) or
host factors.11 To determine why patients have recrudescence
after treatment with artemisinin derivatives, we retrospec-
tively analyzed data and stored parasite isolates from patients
treated with artesunate monotherapy at the Bangkok Hospi-
tal for Tropical Diseases, Thailand, investigating host-related
and parasite-related factors.
MATERIALS AND METHODS
This study was approved by the Ethics Committee of Ma-
hidol University. Unless specified, all chemicals used in the
present study were purchased from Sigma (St. Louis, MO).
Patient recruitment, treatment, and evaluation. Of 320 pa-
tients with falciparum malaria admitted during the period
April 1998–March 1999 to the Bangkok Hospital for Tropical
Diseases, Thailand, 150 patients were treated with artesunate
tablets (600 mg total dose in 3 days; Guilin No. 1 Factory,
Guangxi, China, registered for use in Thailand). Blood was
collected routinely from all malaria patients. Inclusion criteria
were as follows: had a case of acute uncomplicated falciparum
malaria, were >18 years old, had no treatment with artemisi-
nin derivatives during the previous 2 weeks, and gave in-
formed consent. There were 104 patients who met the inclu-
sion criteria for this study. Patients remained in the hospital
for 28 days and had daily blood smears. Blood samples were
taken before treatment on the day of admission and at the
time of recrudescence and were stored in liquid nitrogen.
Routine blood chemistry and hematologic parameters were
determined automatically using a Boehringer Mannheim Hi-
tachi 917 (Boehringer Mannheim, Indianapolis, IN) and Gen
S (Coulter, Hialeah, FL).
The freezing solution for cryopreservation of parasites was
prepared by first filtering a solution of either sorbitol or glyc-
erol (4.2%) in 0.9% sodium chloride, through a 0.45-m filter
(New Bedford, MA). This solution was mixed with 99% glyc-
erol to make a solution containing 3% sorbitol or glycerol,
0.65% sodium chloride, and 28% glycerol. Before cryopres-
ervation, ring-stage patient blood samples were centrifuged at
400×g for 7 minutes at 4°C. The plasma was discarded, and
the cell pellet was mixed with an equal volume of freezing
solution. The mixture was divided into 0.5-ml aliquots, frozen,
and stored in liquid nitrogen.
Parasite density was obtained from thin blood smears: 1,000
erythrocytes were examined, and the number of these in-
fected with plasmodia yielded the percent parasitemia. Para-
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sitemias were calculated as parasites per microliter of blood
(multiplying percent parasitemia and red blood cell [RBC]
counts).
Parasite drug sensitivity tests. Blood samples were thawed,
and the in vitro culture of the blood stage malaria parasite was
performed by candle jar method as described previously using
human AB serum.12 Aliquots were removed and thawed un-
derwater at room temperature. An equal volume of 3.5%
sodium chloride was added, and the mixture was centrifuged
at 400×g for 7 minutes at 4°C. The pellet was washed 3 times
with stock RPMI 1640 medium and resuspended in RPMI.
Parasites were cultured in a candle jar at 37°C until parasit-
emia reached 0.4% to 0.6% and were used for drug sensitivity
assays. Individual isolates were not cultured for equal dura-
tion because culture time depended on starting parasitemia
level; generally, no cultures were >1 month. Sensitivities to
dihydroartemisinin were determined by the microdilution
method using tritiated hypoxanthine incorporation.13 A
2-fold serial dilution of dihydroartemisinin was prepared in a
96-well plate to which a parasitized RBC suspension, mostly
at the ring stage, was added. The plate was incubated at 37°C
for 24 hours in a candle jar. Tritiated hypoxanthine (Amer-
sham, Arlington Heights, IL) was added, after which the plate
was incubated for another 18–20 hours. The infected cell sus-
pension was harvested (Nunc Cell Harvester 8; Nalge Nunc
International, Rochester, NY) and hypoxanthine incorpora-
tion was determined by a scintillation counter (Tricarb 2700
TR; Packard Company).
Hemoglobin typing and measurement of glucose-6-
phosphate dehydrogenase. Hemoglobin type was analyzed by
cellulose acetate electrophoresis according to the method de-
scribed by the manufacturer (Helena Laboratories, Beau-
mont, TX). Hemoglobins are separated at a pH of 8.6 on a
cellulose acetate plate, then stained with Ponceau S. For some
patients, the chromatogram could not distinguish conclusively
between hemoglobin A2 and hemoglobin E. In those cases,
identification was based on the result of anion exchange chro-
matography (see later).
The quantitation of hemoglobin A2 by anion exchange
chromatography was performed according to the method de-
scribed by the manufacturer (Helena Laboratories, Beau-
mont, TX). Under these conditions, hemoglobin A2 was
eluted while normal, and other abnormal hemoglobins were
retained by the resin. The hemoglobin A2 fraction was com-
pared with a total hemoglobin fraction by determining the
absorbance and calculating for the percentage of hemoglobin
A2. If the hemoglobin A2 was <3.5%, then the inconclusive
band on cellulose acetate was considered to be hemoglobin E.
Glucose-6-phosphate dehydrogenase (G6PD) deficiency
was assessed by fluorescent qualitative spot test.14 The reac-
tion mixture containing glucose-6-phosphate (G-6-P), tri-
phosphopyridine nucleotide (TPN), saponin, and oxidized
glutathione (GSSG) in potassium phosphate buffer was
added to the blood samples. After incubation at 37°C for
3 minutes, the mixture was spotted onto a Whatman no. 1
filter paper. In the presence of G6PD, the substrate, G-6-P,
was oxidized to 6-phosphogluconate, while TPN was reduced
(TPNH), resulting in a fluorescent spot under long UV light.
Analysis of strains for prmdr1 polymorphisms. Parasitized
RBCs were harvested from culture when >80% of the para-
sites were trophozoites and stored at −20°C. DNA was ex-
tracted from the pellets using QIAamp DNA minikits
(Qiagen, Valencia, CA). Four regions of the pfmdr1 gene
were polymerase chain reaction (PCR) amplified by modifi-
cations of previously published methods.15,16 Basically, we
performed single-round PCR using the flanking primers de-
scribed in these reports. For all 4 reactions, we used the PCR
conditions described as PCR 184. We did not perform the
second-round, however, allele-specific reaction. Instead, am-
plified DNA was purified and sequenced.17
Statistical analysis. SAS version 8.2 (Cary, NC) was used to
construct logistic regression models, with recrudescence as
the dependent variable. Variables representing patient char-
acteristics and laboratory test results were analyzed individu-
ally first, then multivariate models were constructed to con-
trol for important covariates. For simplicity, the continuous
variable representing number of parasites per microliter of
blood was categorized into a dichotomous variable. The cut-
point for the dichotomous high/low parasitemia was set at
10,000 parasites/l blood, which has been used in the litera-
ture.18 SAS also was used to conduct survival analysis for
modeling time to recrudescence.
RESULTS
Recrudescent rate after artesunate administration. A total
of 104 patients with falciparum malaria were admitted to the
malaria ward of the Hospital for Tropical Diseases and
treated with 600 mg of artesunate for 3 days. All patients
remained in the hospital for 28 days, and 32 patients recru-
desced during their hospital stays (29%).
Characteristics of recrudescent and nonrecrudescent para-
site isolates. Of all the available blood samples, in vitro para-
site cultures were obtained successfully from 6 nonrecrudes-
cent patients and 16 recrudescent patients (on admission and
during the episode of recrudescence) (Figure 1). Because
artesunate is rapidly converted to dihydroartemisinin in vivo,
50% inhibitory concentrations (IC50) for dihydroartemisinin
were determined for each parasite isolate. A Wilcoxon signed
rank test (for recrudescent versus nonrecrudescent patients)
and a paired t-test (for admission versus recrudescent iso-
lates) were used to evaluate differences in IC50. There were
no significant differences in IC50 for parasites from recrudes-
cent patients on admission (0.57 ± 0.44 ng/ml; range, 0.17–1.56
ng/ml) or recrudescence (0.615 ± 0.534 ng/ml; range, 0.12–
1.75) or from nonrecrudescent patients (0.45 ± 0.22 ng/ml;
range, 0.2–0.86 ng/ml).
Because all samples were frozen in liquid nitrogen before
IC50 determination, the effects of freezing and thawing on
IC50 were tested using the laboratory strain (K1). K1 was
frozen and thawed under similar conditions (n  5). The IC50
was 0.38 ± 0.09 ng/ml before and 0.30 ± 0.07 ng/ml after
freeze-thawing. There was no statistically significant differ-
ence using a paired t-test (P  0.87), indicating that freezing,
thawing, and reculturing did not affect the determination
of IC50.
In previous reports, pfmdr1 mutations have been associ-
ated with altered in vitro sensitivity to artemisinins.19–21 Se-
quence polymorphisms in pfmdr1 that may decrease sensitiv-
ity have been reported at several codon positions: N86Y,
Y184F, S1034C, N1042D, and D1246Y. For genotyping ex-
periments, new cultures had to be established from cryopre-
served stabilates. Cultures were obtained successfully from 10
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recrudescent patients (from isolates obtained on admission
and during their recrudescent episodes). We PCR amplified
and sequenced the pfmdr1 genes from the admission and re-
crudescent cultures from these 10 patients. Initial and recru-
descent cultures from 7 of 10 patients had wild-type pfmdr1
genotypes. Isolates from only 3 patients had mutations. In 2 of
these 3 patients, isolates showed the same mutations before
and after treatment (one had the N1042D mutation and the
other was Y184F). In 1 of the 3 patients, the pretreatment
isolate had a Y184F mutation that was not found in the post-
treatment strain, suggesting that the original infection may
have been polyclonal and that the nonmutant strain was re-
sponsible for the recrudescence.
Characteristics of recrudescent and nonrecrudescent pa-
tients. The characteristics of the 32 recrudescent patients and
72 nonrecrudescent patients are shown in Table 1. The ages of
patients with and without recrudescence were similar (25.9 ±
6.8 years and 24.9 ± 8.0 years). Both groups were predomi-
nantly male (69% of recrudescent patients and 63% of non-
recrudescent patients). None of the patients were homozy-
gous for thalassemia. Of 103 patients, 18 (17.3%) were het-
erozygous for hemoglobin E (Hb EA), a type of
-thalassemia, and of 104 patients, 9 (8.7%) had G6PD defi-
ciency. No other abnormal hemoglobin bands were detected.
There were no significant differences between the 2 groups in
admission blood chemistries, mean corpuscular volume, mean
corpuscular hemoglobin concentration, or platelet counts or
in the percentage of patients with G6PD deficiencies or
thalassemic trait.
There were several significant differences between patients
who had recrudescence and patients who did not. First, the
recrudescent patients had higher percent parasitemias on ad-
mission (2.65% versus 0.45% in nonrecrudescent patients).
Second, recrudescent patients had significantly higher RBC
counts, hemoglobin levels, and hematocrits (Table 1). To-
gether, these data suggest that patients with higher parasite
burdens were more likely to have recrudescence. When the
number of parasites per microliter of blood was calculated,
the difference was highly significant (P  0.0035). The only
other variable that was significantly different between recru-
descent and nonrecrudescent patients was the white blood
cell (WBC) count; recrudescent patients had significantly
higher WBC counts than nonrecrudescent patients (6.6 versus
5.7). The odds ratio (OR) for recrudescence for patients hav-
ing WBC counts >5.85 (the median) was 3.08 (95% confi-
dence interval [CI], 1.27–7.44).
Logistic regression was done to confirm the association be-
tween recrudescence and factors found to be significant in
univariate analyses, including RBC count, hematocrit, hemo-
globin level, and percent parasitemia and parasitemia (num-
ber of parasites/l) (Table1). The level of parasitemia was
represented by a dichotomous variable for high/low level of
parasitemia, with 10,000 parasites/l as the cut-point.18 (Simi-
lar results were found when the median, 12,150, was used as
the cut-point.) Many of these factors are either closely related
(RBC count, hemoglobin, and hematocrit) or indirectly re-
lated (i.e., RBC count × percent parasitemia  parasitemia).
The strongest univariate association was with parasitemia,
FIGURE 1. Dihydroartemisinin 50% inhibitory concentrations (IC50) of cultured patient isolates (in ng/ml).
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with an OR of 9.80 for the dichotomous variable (95% CI,
3.11–30.88).
The association of WBC count with recrudescence also was
confirmed with logistic regression (OR, 1.24; 95% CI, 1.00–
1.53). The OR indicates the increase in odds of recrudescence
for each increase of 1,000/L in WBC count. When control-
ling for parasitemia, the OR for recrudescence with increas-
ing WBC count remained approximately the same but lost
significance (OR, 1.20; 95% CI, 0.94–1.53). To explore the
issue of host WBC count and recrudescent malaria, the types
and amounts of WBC were determined. WBC types mea-
sured included eosinophils, basophils, monocytes, lympho-
cytes, and banded and segmented neutrophils. The measure-
ments of each of these WBCs were analyzed as continuous
variables to test for an association with recrudescence (trend)
using logistic regression.
In univariate regression of WBC types, eosinophil, baso-
phil, monocyte, and lymphocyte levels had no association
with recrudescence (data not shown). Band neutrophils had
an OR of 1.01 (95% CI, 1.00–1.02), and segmented neutro-
phils had an OR of 1.00 (95% CI, 1.00–1.01). When control-
ling for parasitemia, segmented neutrophils had an OR of
1.00 (95% CI, 1.00–1.01). The WBC types individually did not
have a meaningful association with recrudescence.
We then evaluated whether time to recrudescence was as-
sociated with any particular host factor. Survival analyses
were performed for all of the variables in Table 1 versus time
to recrudescence. Significant associations were found for
many of the same variables as in bivariate analysis (parasit-
emia, RBC count, hemoglobin level), which suggest that time
to recrudescence depends on the parasite burden. We also
found that time to recrudescence depended on blood urea
nitrogen (BUN) level. Figure 2 shows survival curves of re-
crudescent patients categorized into normal (20 mg/dl) and
high (>20 mg/dl) categories. The hazard ratio decreased sig-
nificantly with the higher level of BUN (P  0.028). Patients
with high BUN levels (and poorer renal function) had recru-
descence later than patients with low BUN levels.
DISCUSSION
To our knowledge, this is the first study to look at risk
factors for failure by artemisinin monotherapy. The predomi-
nant risk factor for recrudescence seems to be a high parasite
burden. Among patients with recrudescences, those with
poorer renal function tended to have recrudescence later.
There were no differences in IC50 values between strains iso-
lated from recrudescent and nonrecrudescent patients on ad-
mission or between admission and recrudescent strains from
patients having recrudescence. Few mutations were found in
the pfmdr1 gene. These data suggest that artemisinin failures
were not due to drug-resistant parasites.
In this study, 31% of patients recrudesced during the 28-
day observation period. Previous studies showed recrudes-
cent rates after treatment with various regimens of artemisi-
nin derivatives of 3–50%.10 Longer periods of treatment are
associated with lower recrudescence rates. Combination with
another drug, such as mefloquine, also reduces the appear-
ance of recrudescence. In some instances, reported recrudes-
cence rates may be artifactually high because reinfections
might be mistaken for recrudescences. In this study, however,
none of the 32 recrudescent patients were cases of reinfec-
tions because all of the patients remained in the hospital in
Bangkok for 28 days, where they had no exposure to infected
mosquitoes, and had recrudescence during that time.
TABLE 1




(n  72) P value*
Age of infected patient (yr) 25.9 (13–41) 26.9 (14–49) NS
Sex of infected patients (M:F) 22:10 45:27 NS
Percent parasitemia on admission 2.65 (0.02–20.20) 0.45 (<0.01–0.40) 0.0106
Parasitemia (per l) 116,000 (590–776,000) 19,000 (30–174,000) 0.0035
Parasitemia, >10,000 per l (no. [%]) 28 (87.5) 30 (41.7) <0.001
Samples with G6PD deficiency (%) 2 (6.3) 7 (9.3) NS†
(n  70)
Hb EA–containing samples (%) 3 (9.4) 16 (21.1) NS†
(n  71)
AST (IU/L) 71.3 (20–315) 53.0 (15–266) NS
ALT (IU/L) 57.9 (5–266) 53.7 (8–211) NS
BUN (mg/dL) 19.25 (3.50–91.20) 13.6 (0.55–62.00) NS
BUN >20 mg/dL (no. [%]) 9 (28.1) 6 (8.3) 0.0284
Alkaline phosphatase (IU/L) 101.5 (53.0–228.8) 109.8 (34.1–279.6) NS
RBC (1 million per l) 4.6 (2.6–6.5) 4.2 (2.2–6.2) 0.030
Hemoglobin (%) 12.3 (7.8–15.7) 11.1 (6.4–16.8) 0.022
Hematocrit (%) 37 (22–48) 34 (19–50) 0.020
MCV (fL) 82 (64–96) 82 (57–98) NS
(n  71)
MCHC (%) 32.9 (31–35) 33 (30–35) NS
(n  71)
WBC (1,000 per l) 6.6 (1.9–13.2) 5.7 (2.1–11.2) 0.053
Platelets (1,000 per l) 90 (11–243) 109 (11–358) NS
(n  30)
Note. Arithmetic means with ranges shown in parentheses (except where noted).
G6PD  glucose-6-phosphate dehydrogenase; AST  aspartate aminotransferase; ALT  alanine aminotransferase; BUN  blood urea nitrogen; RBC  red blood cells; MCV  mean
corpuscular volume; MCHC  mean corpuscular hemoglobin concentration; WBC  white blood cells.
* Student 2-tailed t-test except where noted.
† Fisher exact test.
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As shown in Table 1, the parasite burdens (parasites/l) on
the day of admission of recrudescent patients were signifi-
cantly higher than those of nonrecrudescent patients. Patients
with parasitemias >10,000 parasites/l of blood had 9.8 times
the odds of recrudescence than patients with parasitemias
<10,000 parasites/l. These data are consistent with previous
studies on quinine22 and mefloquine,23 which also showed
that recrudescent patients tended to have higher parasitemias
before treatment than nonrecrudescent patients. A previous
study of artemisinin monotherapy also found higher recru-
descent rates with higher parasitemia; however, the associa-
tion was not as strong as the one reported here.24 Higher
admission parasite burdens could predispose to recrudes-
cence by increasing the likelihood of a parasite escaping de-
struction.
The range of in vitro IC50 values for dihydro-artemisinin
found here (0.14–2.0 ng/ml) are consistent ranges previously
reported for Thai isolates (0.24–8.1 ng/ml25,26). The data pre-
sented here indicate that recrudescence after artesunate treat-
ment was not due to the development of parasite drug resis-
tance. This finding is consistent with in vitro studies on recru-
descence.27
An association was found between high BUN level and
time to recrudescence. Poor renal function may be associated
with later recrudescence, perhaps because it reduces renal
clearance of the drug, allowing the drug to remain at thera-
peutic levels in the plasma for longer periods. A longer du-
ration of therapy may delay or prevent recrudescence; how-
ever, another study did not find longer duration of artesunate
therapy to reduce recrudescence rates.24
One implication of these data is the possibility of offering
longer or different therapies to patients depending on their
initial parasite burdens. Admission parasitemias might be
useful in helping clinicians choose therapeutic regimens.
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